Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Assets Average (2016 - 2025)

Arrowhead Pharmaceuticals' Assets Average history spans 15 years, with the latest figure at $1.5 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 38.82% year-over-year to $1.5 billion; the TTM value through Dec 2025 reached $1.5 billion, up 38.82%, while the annual FY2025 figure was $1.3 billion, 32.53% up from the prior year.
  • Assets Average reached $1.5 billion in Q4 2025 per ARWR's latest filing, up from $1.4 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.5 billion in Q4 2025 to a low of $628.0 million in Q1 2021.
  • Average Assets Average over 5 years is $917.1 million, with a median of $791.2 million recorded in 2022.
  • Peak YoY movement for Assets Average: dropped 12.1% in 2023, then skyrocketed 63.6% in 2025.
  • A 5-year view of Assets Average shows it stood at $674.3 million in 2021, then increased by 17.41% to $791.7 million in 2022, then dropped by 12.1% to $695.9 million in 2023, then soared by 54.72% to $1.1 billion in 2024, then skyrocketed by 38.82% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Assets Average are $1.5 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.5 billion (Q2 2025).